Brind.

Amgen Stock Rises Following Phase 3 Success of Sjögren's Drug

1 report, 1 independent Updated Sep 22
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Amgen completed the acquisition of Horizon Therapeutics on September 22, 2026. Separately, an experimental Amgen drug, dazodalibep, met its primary objective in a Phase 3 trial for Sjögren's syndrome. The drug demonstrated a statistically significant and clinically meaningful improvement on a widely used measure of disease activity after 48 weeks of treatment.

From biopharmadive.com

Why it matters

Some supportBrind's analysis of the reports

The positive trial results drove Amgen's stock price up as much as 5% on Tuesday. Sjögren's syndrome currently lacks approved treatments that can alter the condition's course, making the drug's success notable for the biopharmaceutical market.

From biopharmadive.com

Who's involved

  • AmgenCompleted the acquisition of Horizon Therapeutics and developed the successful drug dazodalibep.
  • Horizon TherapeuticsWas acquired by Amgen and held a drug asset that was discovered by AstraZeneca.
  • AstraZenecaDiscovered a drug asset that was subsequently acquired by Horizon Therapeutics.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • AmgenSpeculative

    Amgen could see increased revenue from the successful pipeline drug, dazodalibep, which targets a condition currently lacking approved treatments.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped